


# Faraday Discussions

Accepted Manuscript



This manuscript will be presented and discussed at a forthcoming Faraday Discussion meeting. All delegates can contribute to the discussion which will be included in the final volume.

**Register now to attend!** Full details of all upcoming meetings: <http://rsc.li/fd-upcoming-meetings>



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

## High-throughput Quantum Cascade Laser (QCL) spectral histopathology: a practical approach towards clinical translation.

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Michael J. Pilling,<sup>a</sup> Alex Henderson,<sup>a</sup> Benjamin Bird<sup>b</sup>, Mick D Brown,<sup>c</sup> Noel W Clarke,<sup>c</sup> Peter Gardner,<sup>d</sup>

Infrared microscopy has become one of the key techniques in the biomedical research field for interrogating tissue. In partnership with multivariate analysis and machine learning techniques, it has become widely accepted as a method which can distinguish between normal and cancerous tissue with both high sensitivity and high specificity<sup>1, 2</sup>. While spectral histopathology (SHP) is highly promising for improved clinical diagnosis, several practical barriers currently exist, which need to be addressed before successful implementation in the clinic. Sample throughput and speed of acquisition are key barriers and have been driven by the high volume of samples awaiting histopathological examination. FTIR chemical imaging utilising FPA technology is currently state-of-the-art for infrared chemical imaging, and recent advances in its technology have dramatically reduced acquisition times. Despite this, infrared microscopy measurements on a tissue micro array (TMA), often encompassing several million spectra takes several hours to acquire. The problem lies with the vast quantities of data which FTIR collects, each pixel in a chemical image is derived from a full infrared spectrum, itself composed of thousands of individual data points. Furthermore data management is quickly becoming a barrier to clinical translation and poses the question of how to store these incessantly growing data sets. Recently<sup>3</sup> doubts have been raised as to whether the full spectral range is actually required for accurate disease diagnosis using SHP. These studies suggest that once spectral biomarkers have been pre-determined it may be possible to diagnose disease based on a limited number of discrete spectral features. In this current study, we explore the possibility of utilising discrete frequency chemical imaging for acquiring high-throughput, high resolution chemical images. Utilising a Quantum Cascade Laser imaging microscope with discrete frequency collection at key diagnostic wavelengths, we demonstrate that we can diagnose prostate cancer with high sensitivity and specificity. Finally we extend the study to a large patient data set utilising tissue micro arrays and show that high sensitivity and specificity can be achieved using high-throughput, rapid data collection, thereby paving the way for practical implementation in the clinic.

### 1 Introduction

Histopathology is currently the gold standard for identifying the manifestation of disease in tissue. Principally relying on changes in morphology and architecture highlighted through selective staining<sup>4, 5</sup>, a highly trained pathologist can diagnose disease, suggest possible treatments and even provide information on likely prognosis. Microscopic examination of stained tissue biopsy sections presents the pathologist with a high degree of information, and histopathology is currently

unsurpassed in its diagnostic accuracy. However, manual examination of individual tissue biopsies is extremely time consuming, with each section being individually interrogated for the presence of abnormalities. Limited throughput inevitably results in significant delays between the time a biopsy is obtained and a diagnosis being made with clear implications for patient care and treatment. Furthermore disease diagnosis based on tissue morphology and architecture is inherently subjective, often resulting in intra and inter observer error<sup>6</sup>. This situation has been exacerbated by national cancer screening programs, with the number of tissue biopsies being harvested increasing annually. Desire for increased throughput, improved accuracy and a reduction in repeat biopsies are clear drivers for the implementation of complementary methods for disease diagnosis.

Over the last decade spectral histopathology (SHP) has demonstrated great promise for the diagnosis of the diseased state. Fourier transform infrared chemical imaging has gained attention in the biomedical field as a rapidly emerging

<sup>a</sup> Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

<sup>b</sup> Daylight Solutions, 15378 Avenue of Science, Suite 200, San Diego, CA 92128-3407, USA

<sup>c</sup> Genito Urinary Cancer Research group, Institute of Cancer Sciences, Paterson Building, The University of Manchester, Wilmslow Road, Manchester, M20 4BX

<sup>d</sup> Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. E-mail: Peter.Gardner@Manchester.ac.uk; Fax: +44 (0)161 306 5201; Tel: +44 (0)161 306 4463.

technology for disease diagnosis<sup>7, 8</sup>. Biological material can be interrogated without the need for exogenous labels, little or no sample preparation, and in a non-destructive manner. The technique exploits the high chemical sensitivity of infrared spectroscopy, in combination with microscopy, to provide spatially resolved measurements that are rich in biochemical content. Whereas conventional histology relies on the subjective interpretation of tissue architecture and cellular morphology, this approach relies on reproducible physical measurements of sample chemistry, and the potential to reduce misdiagnosis.

In partnership with machine learning methods, FTIR chemical imaging has demonstrated the ability to distinguish between normal and cancerous tissue with high sensitivity and specificity<sup>9, 10</sup>, and also to determine cancer grade<sup>11</sup> and staging<sup>12</sup>. However, clinical translation has been inhibited until recently by technological advancements failing to deliver what is required to make it competitive with current histological methods. Developments in focal plane array (FPA) detector technology<sup>13</sup> have drastically reduced acquisition times, but until recently<sup>14</sup> could not compete with the high-resolution images obtainable in Brightfield imaging. Early signs of invasive cancer are often manifested in the basement membrane, the basal layer in prostate<sup>15</sup> and myoepithelium in breast cancer<sup>16, 17</sup>. Conclusive early diagnosis requires detection of subtle changes on the sub-cellular level across microscopic membranes only obtainable through high-quality high-resolution chemical images.

Recent technological advancements have resulted in commercially available infrared microscopes utilising 0.62 NA 15X magnification optics with a 128x128 FPA enabling imaging of a 140  $\mu\text{m}$  x 140  $\mu\text{m}$  area to be imaged as a single measurement with 1.1  $\mu\text{m}$  pixel size and a diffraction-limited spatial resolution of about 6  $\mu\text{m}$  at 1667  $\text{cm}^{-1}$ . However the inherent trade-off between high-resolution and acquisition times inevitably makes high resolution imaging impractical due to excessive measurement times. Obtaining high-resolution (1.1  $\mu\text{m}$ ) chemical images from a single 1 mm tissue micro array (TMA) core will typically take between 5-6 hours to acquire followed by a further 40-50 minutes to process the interferograms and stitch the tiles together<sup>18</sup>. The time taken to record single cores generally makes FTIR chemical imaging, even using 128x128 FPA unsuitable for high throughput imaging of tissue biopsies and full TMA's. The problem lies with the vast quantities of data an FTIR chemical imaging system acquires when using an FPA detector. A single infrared tile consists of 16384 pixels (for a 128x128 FPA) and each pixel itself consists of an entire infrared spectrum. Imaging a full TMA core with 1 mm diameter at 1.1  $\mu\text{m}$  pixel resolution is typically performed using 64 infrared tiles, resulting in a large spectral datacube requiring over 13GB to store. Since FTIR relies on the Fellgett advantage and collects all wavelengths simultaneously, restricting the spectral range does not reduce the acquisition time. Speed of acquisition and data management issues are rapidly becoming a significant barrier to clinical translation.

Recently, doubts have been raised as to whether entire infrared spectra are necessary for disease diagnosis using SHP. Studies suggest that once spectral biomarkers have been identified, it may be possible to use a selection of key wavelengths for diagnosing disease<sup>3, 19, 20</sup>. In this paper we report on a novel study using discrete frequency imaging utilising a Spero Quantum Cascade Laser (QCL) based full-field imaging infrared microscope for disease diagnosis. We investigate the practicalities of utilising high-resolution, high-throughput chemical imaging using discrete frequencies and consider implications for improved disease diagnosis.

## 2 Materials and methods

### 2.1 Sample Preparation

Formalin-fixed, paraffin embedded prostate tissue samples were obtained following informed consent and ethical approval (Trent Multi-centre Research Ethics Committee 01/4/061). A 12  $\mu\text{m}$  thick section was taken from each paraffin block and fixed to a BaF<sub>2</sub> slide (75mmx25mmx1mm) for infrared transmission measurements. BaF<sub>2</sub> was chosen since it has a better low wavenumber cut-off than CaF<sub>2</sub> (950  $\text{cm}^{-1}$  compared with 1000  $\text{cm}^{-1}$ ) and does not suffer from the electric field standing wave effect<sup>21-24</sup> which can be a problem for low-e infrared reflecting slides. Serial sections from each block were fixed to glass and underwent Haematoxylin and Eosin (H&E) staining for Brightfield imaging. The samples mounted on BaF<sub>2</sub> were left in wax and did not undergo deparaffinization. This reduces the risk of further chemical alterations from clearing solvents, and reduces Mie scattering via refractive index matching<sup>25, 26</sup>.

### 2.2 Infrared Chemical Imaging

Infrared chemical images were acquired with a Spero infrared microscope (Daylight Solutions Inc., San Diego, CA, USA) utilising quantum cascade laser technology<sup>27</sup>. Employing four separate high-brightness QCL modules in a single multiplexed source enables continuous access to the fingerprint region between 900-1800  $\text{cm}^{-1}$ . The system is equipped with a high-pixel density (480x480) uncooled microbolometer FPA. A 0.7 NA, 12.5X compound refractive objective was used in transmission mode, providing a large field of view of 650  $\mu\text{m}$  x 650  $\mu\text{m}$  with a corresponding pixel size of 1.35  $\mu\text{m}$  yielding a diffraction-limited spatial resolution of about 5  $\mu\text{m}$  at 1667  $\text{cm}^{-1}$ .

The tissue used in the study arise from 29 separate cancer patients consisting of 50 unique 1 mm diameter cores spread over two separate TMA's. Each core is assigned as either cancerous (containing malignant tissue), or normal associated (from a cancer patient but containing no malignant tissue). Wherever possible a normal core and a cancerous core were measured for each patient. However this was not always possible due to some cores being missing from the array. The sample set consisted of an equal number of 25 normal associated and 25 cancerous cores. Background images were collected prior to each TMA core, taken

from a clean area of the sample that was free of tissue or paraffin. Chemical images of each TMA core were collected using the mosaic method, with each core measured individually as a 2x2 mosaic. A single core using 27 discrete wavelengths consisting of 921600 pixels took approximately 5 minutes and 30 seconds to collect. Each sample tile is ratioed to its background in real-time and, upon completion of the collection, automatically exported as a datacube in MATLAB format ready for stitching post collection.

### 2.3 Data Pre-processing

Data pre-processing was performed using MATLAB 2013a (The MathWorks Inc., Natick, MA, USA) and the ProSpect Toolbox (London Spectroscopy Ltd., London, UK). Infrared tiles were stitched together using software written in house and saved as a 960x960x27 hyperspectral datacube, and also as a chemical image based on the intensity of the amide I band. Stitching together 4 tiles to form a hyperspectral data cube using a dual core Intel i7-2600 with 16MB RAM took on average just 6 seconds per core and required only 80MB of storage space. Spectra were quality tested to remove areas of the images where no tissue was present, or where there was a high degree of scattering. Quality testing was based on the intensity of the amide I band, with those spectra having amide I absorbance between 0.1-2.0 being retained. Each spectrum was baseline corrected using a linear rubber band correction at 1000  $\text{cm}^{-1}$  and 1734  $\text{cm}^{-1}$ . Finally the spectra were normalised to the intensity of the amide I band to account for different thicknesses of the tissue sample.

## 3 Results and Discussion

### 3.1 Wavelength Selection for Discrete Frequency Imaging

Successful exploitation of discrete frequency chemical imaging for high-throughput disease diagnosis requires the intelligent selection of salient frequencies that provide the greatest discriminatory power between diseased and healthy states. Failure to choose the correct wavelengths could result in crucial spectral biomarkers being missed and directly impact diagnostic accuracy. In addition, not all wavelengths are suitable biomarkers and often provide little or no useful biochemical information. Acquiring too many wavelengths increases measurement times and therefore reduces throughput. Numerous examples exist in the literature of well-established biomarkers<sup>28, 29</sup> determined using FTIR chemical imaging. However, to date no studies have been performed on the transferability of biomarkers obtained using FTIR to discrete frequency IR spectroscopy. We have addressed this by acquiring full band spectra and subsequently identifying key biomarkers at sparsely located frequencies.

Chemical images were acquired in the spectral range 1000  $\text{cm}^{-1}$  - 1800  $\text{cm}^{-1}$  from two patient tissue cores who had been diagnosed with prostate cancer. The first patient core was histologically classified as Normal Associated Tissue (NAT) and contained normal

tissue components only. The second patient core was classified as cancerous and was described morphological features consistent with a Gleason grade of 4. Since the cores available for the study had Gleason grades ranging between 3 and 5, choosing a core with a Gleason grade of 4 encompasses the middle of the cancer severity range. In principle, utilising a larger patient set for acquiring continuous infrared spectra would enable improved identification of the key wavelengths. However, for the scope of this proof of concept study and due to the limited time available, we elected to choose a normal core and a cancerous core in the middle of the cancer severity range. Chemical images for each core based on the intensity of the amide I band are shown in figure 1.




Figure 1 : QCL chemical images of the amide I band intensity and H&E stained serial section (bottom) for normal associated tissue (left) and cancerous tissue (right) used to identify the key wavelengths for discrete frequency classification

Employing similar methods as Fernandez<sup>20</sup>, a database was constructed consisting of 5000 spectra each for cancerous epithelium and normal associated epithelium. The spectra were quality tested, truncated between 1350  $\text{cm}^{-1}$  - 1500  $\text{cm}^{-1}$  (to remove spectral regions describing bands of paraffin), and normalised to the amide I band. Mean spectra of the normal associated and cancerous epithelium tissue are displayed in figure 2. Upon first inspection the spectra appear relatively similar, although some subtle differences can be discerned between 1000  $\text{cm}^{-1}$  - 1300  $\text{cm}^{-1}$ .

Half of the spectra from each class were selected at random and fed into a Random Forest<sup>30</sup> algorithm (software available from <http://code.google.com/p/randomforest-matlab/>). Random Forests have the advantage that, unlike other supervised classifiers, they do not require feature selection prior to use. A Random Forest will return a measure for variable importance and identify the most important wavelengths for classification. Alternative methods for wavelength selection are available such as partial least squares discriminant analysis (PLS-DA) and variable importance for

projection (VIP) as described by Lloyd<sup>31</sup>. The classifier was trained using 500 trees with the number of wavelengths selected at random to try and split each node (mtry) set to 2. The remainder of the spectra in the database that had not been used for training were used to test the model.

Receiver operator curves present an effective way to visualise the performance of the classifier. Each tree votes to classify a spectrum to a specific class, and the number of votes provide a probability estimate to each spectrum belonging to a particular class. Varying the probability acceptance thresholds adjusts the trade-off between sensitivity and specificity and produces a receiver operator curve (ROC). The ROC's obtained using the Random Forest classifier are displayed in figure 3.




Figure 2 : Mean spectra for normal associated epithelium and cancerous epithelium from the database constructed from two prostate tissue cores following truncation to remove the spectral regions describing wax, and normalisation to the 1652  $\text{cm}^{-1}$  band.




Figure 3 : Receiver Operator Curves for normal and cancerous epithelium spectra using 2500 from each class for training and testing.  $\text{AUC}=0.9991$

The optimal situation would be for curves to be situated at the top left hand corner of the plot, which indicates both high sensitivity and high specificity. Conversely, a poor classifier would be shown as a plot close to a diagonal line between the origin and top right corner. Area under the curve (AUC) is a widely accepted measure of classifier performance. AUC for the plot shown in Figure 3 is 0.991 demonstrating high-performance of the classifier. Setting a probability of acceptance threshold of 0.5 enables a confusion matrix to be calculated and the ability to determine the proportion of each class that are correctly classified. Table 1 shows that normal associated epithelium spectra are correctly classified with an accuracy of 97.25%, and cancerous epithelium with an accuracy 97.19%.

	Normal	Cancer
Normal	97.25	2.25
Cancer	2.81	97.19

Table 1: Confusion matrix showing classification accuracy for normal associated and cancerous epithelium using the Random Forest classifier with 500 trees

Wavelengths were then ranked in order of variable importance using a GINI importance plot to determine which were most important in distinguishing between normal and cancerous epithelium. Fig 4 a and 4b show typical GINI plots used to select the 25 most important features. The top 25 wavelengths from a single GINI plot were selected for data collection. Subsequent repetition of the analysis shows that the first 14 wavelength are consistently in the top 16 but the remaining 11 wavelengths selected can be ranked as far down as 58. This is not too surprising given that the difference in importance starts to drop off significantly after 20.

The twenty five discriminating wavelengths that were originally used in order of variable importance are shown in Table 2. The selected wavelengths broadly overlap absorption bands centred at 1032  $\text{cm}^{-1}$  ( $\nu(\text{C-O})$  glycogen), 1080  $\text{cm}^{-1}$  ( $\nu_s(\text{PO}_2^-)$ ), 1236  $\text{cm}^{-1}$  ( $\nu_{as}(\text{PO}_2^-)$ ), 1540  $\text{cm}^{-1}$  (amide II), 1656  $\text{cm}^{-1}$  (amide I).




Figure 4 : (a) GINI importance plot as a function of wavelength and (b) ranked in order of variable importance

Wavenumber/cm <sup>-1</sup>							
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1024	1020	1028	1016	1012	1072	1000	1004
(9)	(10)	(11)	(12)	(13)	(14)	(15)	(16)
1032	1636	1068	1088	1684	1092	1008	1640
(17)	(18)	(19)	(20)	(21)	(22)	(23)	(24)
1688	1692	1064	1648	1236	1696	1096	1524
(25)							
1044							

Table 2 : 25 key wavenumbers / cm<sup>-1</sup> ranked in order of variable importance as identified by the random forest classifier. Figures in parentheses indicate the variable importance ranking with the lowest number being the highest ranking.

### 3.2 Discrete frequency imaging and classification

Discrete frequency chemical images were acquired from each of the 50 prostate tissue biopsy cores. Two additional wavelengths at 1652 cm<sup>-1</sup> and 1734 cm<sup>-1</sup> to the twenty five key wavelengths (Table 2) were also used, to enable the spectra to be quality tested based on the difference in absorption peak intensity at these two wavelengths as the peak height of the amide I band. Figure 5 shows chemical images from a single prostate tissue core based on the intensity of the 1652 cm<sup>-1</sup>, 1524 cm<sup>-1</sup>, 1236 cm<sup>-1</sup> bands and the H&E stained serial section. The chemical images shown have been quality tested and spectra with amide I peak absorbance intensity between 0.1-2.0 retained. The image illustrates that rapid chemical imaging using discrete frequencies enables different types of tissue to be highlighted depending on the chosen frequency. Chemical images obtained at 1652 cm<sup>-1</sup> and 1524 cm<sup>-1</sup> enable differentiation between epithelium and stroma while the 1236 cm<sup>-1</sup> chemical image highlights regions of stroma.




Figure 5 : Discrete frequency chemical images of a prostate tissue single core obtained using (clockwise from top left) 1652 cm<sup>-1</sup>, 1524 cm<sup>-1</sup>, 1236 cm<sup>-1</sup> band intensity and H&E stained serial section.

Chemical images from each of the 50 cores were compared to the corresponding H&E stained serial sections to identify regions of cancerous and normal associated epithelium. The patients were then randomly divided into two separate libraries to form a training cohort (15 patients) and a testing cohort (14 patients). The patients in each cohort were fairly evenly distributed across the two separate TMA slides. The training cohort had a split of 8 patients on one slide and 7 on the other. While the testing cohort was split by 8 patients on one slide and 6 on the second slide. Using the

methods previously described by Fernandez<sup>20</sup>, two spectral databases were constructed from these cohorts consisting of a training data set and an independent test set. Dividing the patients (and the data) prior to building the classifier ensures that the test set is completely independent since no spectra used in training the model will be used for testing. Equal numbers of spectra from each class (normal associated and cancerous epithelium) were extracted from the training database. Spectra were quality tested, baseline corrected and normalised to the amide I band. The mean cancerous epithelium and normal epithelium spectra based on 207505 measurements each are shown in Figure 6. Despite the limited number of data points in each spectrum, subtle spectral differences between the two classes are discernible, particularly between  $1000\text{ cm}^{-1}$  -  $1240\text{ cm}^{-1}$ .

Half the spectra contained in the training database were randomly selected to train the model, with the remainder forming a validation test set. Metrics fed into the classifier were based on the absorbance values for each of the 25 discrete frequencies, and also ratios of absorbances for each individual wavelength which yielded 325 features in total. The Random Forest classifier was then trained on the 207505 partitioned spectra using 200 trees which enabled the classifier to be constructed in approximately 90 minutes. The remaining spectra in the training data base were used to validate the model. The receiver operator curves obtained are displayed in figure 7. AUC values for the classifier are close to 1 (0.9895) indicating that the classifier can easily differentiate between normal and cancerous epithelium spectra. Despite utilising only 25 wavelengths the correctness of classification is high with sensitivity and specificity of 93.39% and 94.72% respectively, as shown by the confusion matrix in Table 3.

The large number of features used to train the Random Forest classifier, and the substantial size of the data set, are the main factors responsible for lengthy training times. In an attempt to speed up training, the classifier was also trained using only the absorbance values at each of the 25 discrete frequencies. Training using 207505 spectra per class using 200 trees enabled the Random Forest classifier to be constructed in just 8 minutes. The ROC's obtained using 25 features are shown in Figure 8. The reduction in the features used in training has an impact on the performance of the classifier, the AUC decreasing from 0.9895 to 0.9625. Furthermore the sensitivity and specificity decreases to 89.14% and 90.32% respectively, suggesting that despite the increased processing times, using 325 features constructed from the 25 discrete frequencies is more effective.




Figure 6: Discrete frequency mean spectra utilising 27 wavelengths for cancerous and normal associated epithelium. Dashed lines are present as a guide to the eye.




Figure 7: Receiver operator curves (ROC) with 25 wavelengths (325 features) using validation data for normal associated and cancerous epithelium. Area under the curve values (AUC) are normal=0.9851, cancer=0.9851.

	Normal	Cancer
Normal	93.39%	6.61%
Cancer	5.28%	94.72%

Table 3 : Confusion matrix showing correctness of classification using 25 wavelengths for normal and cancerous epithelium




Figure 8 : Receiver operator curves (ROC) with 25 wavelengths (25 features) using validation data for normal associated and cancerous epithelium. Area under the curve values (AUC) are normal=0.9625, cancer=0.9625.

The training data was then subjected to repeated random sub-sampling validation using ten repeats. In each case half the spectra in the database were randomly selected and used for training, while the remainder served as validation spectra. Table 4 shows the mean and standard deviation for the calculated sensitivity and specificity of the ten classifiers trained. The mean sensitivity and specificity from the repeated subsampling is high and provides a very small standard deviation indicating the classifier accuracy is not dependent on the spectra used to train and test the model.

	Sensitivity	Specificity
Mean	94.60%	93.39%
Standard deviation	0.0012	0.0010

Table 4: Mean and standard deviation of sensitivity, specificity, obtained using repeated random sub-sampling validation of ten trained classifiers.

### 3.3 Discrete frequency classification with restricted numbers of wavelengths

While it is evident that 25 discrete wavelengths allows good classification accuracy on the validation data set, the effect of the number of discrete wavelengths measured on classification accuracy is a key question. Clinical translation of discrete frequency infrared imaging requires high-throughput, high-resolution imaging utilising as few discrete wavelengths as possible. Naturally, there will be a trade-off between the number of wavelengths acquired and the classification accuracy. We have addressed this by reducing the number of wavelengths used to train the model. We elected to reduce the number of wavelengths used in classification rather than re-measuring all the cores with the respective number of wavelengths due to time considerations and the desire for better comparability. In each case the sub-set of wavelengths used were

those with the highest variable importance values (table 2), to ensure optimal classifier performance. Six separate experiments were performed on the training database using varying numbers of discrete wavelengths. Table 5 details the discrete wavelengths used for training and validating the Random Forest classification model.

Number of discrete wavelengths	Discrete wavelengths / $\text{cm}^{-1}$ used for Random Forest classification									
	20	1024 1636 1064	1020 1068 1648	1028 1088	1016 1684	1012 1092	1072 1008	1000 1640	1004 1688	1032 1692
18	1024 1636	1020 1068	1028 1088	1016 1684	1012 1092	1072 1008	1000 1640	1004 1688	1032 1692	
16	1024 1636	1020 1068	1028 1088	1016 1684	1012 1092	1072 1008	1000 1640	1004	1032	
14	1024 1636	1020 1068	1028 1088	1016 1684	1012 1092	1072	1000	1004	1032	
12	1024 1636	1020 1068	1028 1088	1016	1012	1072	1000	1004	1032	
10	1024 1636	1020	1028	1016	1012	1072	1000	1004	1032	

Table 5 : Discrete wavelengths used for training the classifier with 20, 18, 16, 14, 12, and 10 different wavelengths

The performance of each classifier is shown in the ROC's in Figures 9(a-f). Decreasing the number of wavelengths used in classification reduces the performance of the classifier as observed by the AUC values of 0.9780 and 0.9739 for 20 and 18 wavelengths respectively. Reducing the number of discrete frequencies is expected to reduce classifier performance since less information is being used during training. Surprisingly, training the random forest with just 18 wavelengths still enables excellent discrimination between normal associated and cancerous epithelium tissue. Reducing the numbers of wavelengths further to 16 discrete frequencies only has a marginal effect on classifier performance (AUC=0.9772). However when using 12 or 10 discrete frequencies the classifier performance begins to deteriorate with AUC values of 0.9557 and 0.9421 respectively.

AUC values provide a good comparison on classification accuracy, however a more meaningful measure is the proportion of correctly classified spectra. Table 6 shows the proportion of correctly classified cancerous (sensitivity) and normal associated epithelium (specificity) as a function of the discrete frequencies used in classification. The values for sensitivity and specificity are the mean values based on repeated random sub-sampling using ten repeats.

Number of Discrete Frequencies	25	20	18	16	14	12	10
Sensitivity (%)	94.60	93.02	92.27	91.88	91.13	89.11	87.15
Specificity (%)	93.39	91.71	91.16	91.03	90.05	88.53	86.80

Table 6: Table showing sensitivity and specificity for the validation data using random subset sampling using ten repeats



The sensitivity and specificity are broadly in line with the AUC values, and using all 25 wavelengths enables high classification accuracy. Reducing the number of discrete frequencies to 16 still results in good classification accuracy with sensitivity and specificity of 91.88 % and 91.03 % respectively. Performance of the classifier becomes poorer when using 12 or less discrete frequencies. However using only 10 wavelengths still enables surprisingly good classification accuracy with sensitivity and specificity of 87.15 % and 86.80 %. Inspection of Figure 9(f) reveals that, when using 10 discrete frequencies, the majority of the wavelengths are in the range  $1000\text{ cm}^{-1}$ - $1072\text{ cm}^{-1}$ , indicating important spectral biomarkers are located here.

The number of discrete frequencies chosen when acquiring chemical images is a key parameter. However the time penalty associated with collecting increasing numbers of discrete frequencies is also an important consideration. Furthermore, as the number of discrete frequencies increase, so does the time required to train the Random Forest classifier. The performance of the Random Forest classifier as a function of AUC, sensitivity, specificity, acquisition time per core, and training time are shown in Table 7.

No. of frequencies	AUC	Sensitivity	Specificity	Collection time per core/min	Training time /min
25	0.9851	94.60	93.39	5.5	90
20	0.9780	93.02	91.71	4.47	60
18	0.9739	92.27	91.16	4.33	48
16	0.9772	91.88	91.03	4.13	37
14	0.9669	91.13	90.05	4	32
12	0.9557	89.11	88.53	3.6	24
10	0.9421	87.15	86.80	3.27	17

Table 7 : Table showing AUC, sensitivity, specificity, collection time per core, and classifier training time as a function of the number of discrete frequencies used with Random Forest classifier

The resulting sensitivity and selectivity are excellent when using the full 25 discrete frequencies, and a single core can be measured in 5.5 minutes which is a reasonable timescale. However constructing the classifier takes the longest time at ca. 90 minutes. Utilising only 10 discrete frequencies enables fast data acquisition (3.27 minutes), and the Random Forest classifier can be constructed in just 17 minutes. However the improved throughput and analysis time is offset by the reduced sensitivity and specificity of 87.15% and 86.80% respectively. To put this into perspective it is crucial to understand what timescales would be clinically acceptable. Once the classifier has been trained and robustly validated there would not be a requirement to retrain the classifier on a regular basis. Therefore, provided that the classifier can be trained within reasonable timescales then the key parameter is the collection time per core. Utilising between 14-16 discrete frequencies enables each core to be measured in approximately 4 minutes while maintaining sensitivity and specificity >90%. Although there is a

slight reduction in sensitivity and specificity compared to utilising the full 25 discrete frequencies, there is a considerable time saving of approximately 90 seconds per core. We would suggest that acquiring high-resolution images of a single TMA acquired in just four minutes, while maintaining high sensitivity and specificity would be clinically acceptable.

As QCL-based, full-field imaging technology continues to advance over the coming years, this tradeoff will become less apparent to the clinician. The underlying technology employed in this work is scalable and has the potential to reach data collection times 1-2 orders of magnitude shorter, limited by the thermal time constant of the bolometer (typically 0.33/fps) and the time required to step the stage a single FOV when building mosaic images. Even today, if a slightly lower pixel resolution of  $4.25\text{ }\mu\text{m}$  is deemed acceptable for the application, a 9.5X increase in throughput could be achieved simply by using the 0.3NA 4X objective with a 2mm x 2mm FOV. In this configuration, tissue cores with diameters up to 2 mm could be imaged in a quarter of the times reported in this work. Current and expected future trends in data acquisition times as a function of the number of discrete wavelengths employed in the diagnostic for two different area-pixel resolution configurations are shown in Figure 10.




Figure 9 Receiver operator curves using validation data for normal associated and cancerous epithelium with (a) 20, (b) 18, (c) 16, (d) 14, (e) 12 and f (10) discrete frequencies. AUC values are 0.9780, 0.9739, 0.9720, 0.9669, 0.9557 and 0.9421 respectively.

Estimating future throughput trends assumed two camera frames (at 30 fps) are used per discrete wavelength to ensure adequate settling and 125 msec stage mosaic step times. Based on these results, it becomes immediately apparent that whole-slide diagnostic imaging could eventually be completed in a matter of minutes using the protocols developed in this work.




Figure 10. Data acquisition times vs. the number of discrete wavelengths included in the diagnostic for the current and future QCL full-field imaging technology used in this work. Two different imaging configurations were used in this analysis: (1) 1.3 mm x 1.3 mm (2x2 mosaic) at 1.35  $\mu\text{m}$  pixel size (this work), and 2.0 mm x 2.0 mm (single FOV) at 4.25  $\mu\text{m}$  pixel size.

### 3.4 Discrete frequency classification : Independent test set

Testing classifier performance using the same patients for training and testing is likely to produce favourable results since inter-patient variability does not become a factor. Implementation of SHP in the clinic requires that good classification of disease state can be achieved as new patients are introduced. Confidence in SHP using discrete frequency imaging can only be achieved if it performs well on patients in an independent test set. Each random forest classifier was used to classify epithelium spectra from the 14 patients in the independent test set. The ROC's obtained in each case are shown in figures 11(a-f) and 12. Figure 11(a) shows the ROC obtained when using 25 discrete frequencies for training and classification on the independent test set. The AUC values which were obtained for the validation set were observed to be all close to 1, indicating good discrimination between classes when training and testing occurs on the same patients. However testing the classifier on the independent test set reduces the AUC values from 0.9851 for the validation data to 0.8395 for the independent test set. Reduced classification accuracy is expected to occur for the independent test, since the data used to test the model are from new patients and therefore completely independent. Reducing the number of discrete frequencies decreases AUC values for the independent test set, in a similar manner observed for the training data set. The AUC value of 0.8396 obtained using 20 discrete frequencies instead of 25 (0.8395) are very similar, indicating

classification performance has not deteriorated significantly. Although there is a slight reduction in AUC (0.8163) when using 16 wavelengths each ROC plot appears broadly similar. Classification performance only appears to deteriorate significantly when utilising 14 or less discrete frequencies. Using only 10 discrete frequencies (figure 12) the AUC value decreases to 0.7808, which is in stark contrast to the validation set which had an AUC value of 0.9421.

The effect of reducing the number of discrete frequencies on sensitivity and specificity is shown in Table 8. Utilising the full 25 discrete frequencies enables reasonable classification accuracy rates of 72.14% and 80.23% for sensitivity and specificity respectively. Reducing the number of discrete frequencies to 16 only has a limited impact on classification with sensitivity and specificity values of 70.46% and 78.10%. In contrast to the validation set the sensitivity does not appear to deteriorate significantly when reducing the number of discrete frequencies. Specificity, however, does appear to be strongly correlated to the number of discrete frequencies and performance drops off sharply when less than 14 wavelengths are used. When using only 10 wavelengths the classification of the independent test set is poorer with a mean sensitivity and specificity of 68.73% and 73.51% respectively.

The poorer performance of the classifiers on the independent test set is surprising considering the excellent classifier performance using the training data. Since all patients in this study have been diagnosed with prostate cancer, there is likely to be considerable biochemical variability between patients. To perform well on new patients the model needs to be trained on a dataset which encompasses this variation. Given the limited patients numbers available in this study for training and testing, it is likely that the model did not have sufficient variability built in to enable good discrimination between normal and cancerous tissue for new patients. Similar findings have been published by Pounder<sup>32</sup> when using spectral histology of breast tissue using FTIR chemical imaging. In their study good classification performance was observed on the training data for classifying epithelium, lymphocytes and myofibroblast rich stroma with AUC values of 0.94. Upon classifying an independent test set there was a deterioration in classifier performance with AUC values in the range of 0.8-0.88. The authors described this effect as being due to the limited number of cores (50) and patients used in the study. These findings are broadly in line with the classifier performance which we have detailed in this paper. We have also considered whether instrumental or sample preparation parameters could be a contributory factor to the poorer classification accuracy of the independent test set. Variability in sample and substrate thickness, and whether the samples are left in wax or dewaxed are all parameters which could potentially affect classifier performance. However a much larger study investigating the effect of each parameter will be required to determine the optimum parameters for classification performance. Another possibility for the poorer classification on the independent test set is the selection of the salient spectral frequencies. In this proof of concept study only two patients were used for selecting the spectral frequencies used to train and test the model. Given the biochemical variability within a

patient population, it is unlikely that two patients are a sufficiently large dataset for identifying the key biomarkers. In the future it is recommended that a larger patient population is used for frequency collection and this is planned to be conducted. Although our preliminary results are promising, larger studies using a more diverse patient database would be required to fully evaluate the full potential of discrete frequency imaging for disease diagnosis.




Figure 11 Receiver operator curves using the independent test set for normal associated and cancerous epithelium with (a) 25, (b) 20, (c) 18, (d) 16, (e) 14, and (f) 12 discrete frequencies. AUC values are 0.8395, 0.8396, 0.8261, 0.8163, 0.8044 and 0.7876 respectively.




Figure 12 : Receiver operator curves (ROC) with 10 wavelengths using independent test set for normal associated and cancerous epithelium. Area under the curve (AUC) values are 0.7808.

Discrete Frequencies	25	20	18	16	14	12	10
Sensitivity (%)	72.14	71.29	71.13	70.46	69.48	68.25	68.73
Specificity (%)	80.23	80.83	78.86	78.10	76.69	75.07	73.51

Table 8 : Table showing sensitivity and specificity for the independent test set using random subset sampling for ten trained classifiers

## Conclusions

Discrete frequency infrared chemical imaging has the potential to provide high-resolution, high-throughput chemical images on a timescale which could revolutionise spectral histopathology. In this study, we have demonstrated that high quality chemical images of tissue biopsy cores comprised of almost a million pixels can be obtained in a matter of minutes. Comparable chemical images obtained on a state of the art FTIR system using an FPA detector would have taken several hours. We have clearly demonstrated that on a validation set that, excellent classifier performance can be achieved by careful selection of discrete frequencies. We have further shown that significant time advantages can be achieved by using just 16 discrete frequencies while maintaining good classification accuracy. Testing the classifier on an independent test set produced mixed results, with poorer accuracy than on the validation set. However, reasonable classification accuracy could still be achieved when using 16 or more discrete frequencies. Classifier performance may have been compromised by only using two patients for selecting the optimal wavelengths. Utilising a larger patient population for determining the key biomarkers will be important in any future studies. Limitations on the number of patient tissue core biopsy samples available are the most likely

cause of the reduced accuracy when testing on new patients. Prospects for this new and exciting technology are bright. However, further work needs to be performed on significantly larger patient numbers to fully understand its potential for successful implementation into the clinic.

## Acknowledgements

We would like to thank Daylight Solutions for making the Spero infrared microscope available to us for the duration of the study. We would also like to acknowledge Jeremy Rowlette, Edeline Fotheringham, Miles Weida, Bill Mohar and Matthew Barre for their help on the project and also for their role during informative discussions. PG and MP would like to acknowledge EPSRC for funding (EP/K02311X/1, EP/L012952/1).

## Notes and references

1. B. Bird, M. Miljkovi, S. Remiszewski, A. Akalin, M. Kon and M. Diem, *Laboratory Investigation*, 2012, 92, 1358-1373.
2. N. Bergner, B. F. M. Romeike, R. Reichart, R. Kalf, C. Krafft and J. Popp, *Analyst*, 2013, 138, 3983-3990.
3. P. Bassan, J. Mellor, J. Shapiro, K. J. Williams, M. P. Lisanti and P. Gardner, *Analytical Chemistry*, 2014, 86, 1648-1653.
4. L. G. Luna, *Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology* (McGraw Hill, New York), 1968.
5. W. P. Michael H Ross, *Histology a text and atlas*, Lippincott Williams & Wilkins, 6th edn.
6. J. B. Lattouf and F. Saad, *BJU international*, 2002, 90, 694-698; discussion 698-699.
7. H. Fabian, P. Lasch, M. Boese and W. Haensch, *Biopolymers - Biospectroscopy Section*, 2002, 67, 354-357.
8. B. R. Wood, L. Chiriboga, H. Yee, M. A. Quinn, D. McNaughton and M. Diem, *Gynecologic Oncology*, 2004, 93, 59-68.
9. M. J. Baker, E. Gazi, M. D. Brown, J. H. Shanks, N. W. Clarke and P. Gardner, *Journal of Biophotonics*, 2009, 2, 104-113.
10. A. Akalin, B. Bird, X. Mu, M. A. Kon, A. Ergin, S. H. Remiszewski, C. M. Thompson, D. J. Raz and M. Diem, *Lab Invest*, 2015, 95, 406-421.
11. E. Gazi, M. Baker, J. Dwyer, N. P. Lockyer, P. Gardner, J. H. Shanks, R. S. Reeve, C. A. Hart, N. W. Clarke and M. D. Brown, *European Urology*, 2006, 50, 750-761.
12. N. Wald and E. Goormaghtigh, *Analyst*, 2015, 140, 2144-2155.
13. K. M. Dorling and M. J. Baker, *Trends in Biotechnology*, 2013, 31, 437-438.
14. M. J. Walsh, D. Mayerich, A. Kajdacsy-Balla and R. Bhargava, 2012.

## ARTICLE

Journal Name

15. A. Liu, L. Wei, W. A. Gardner, C.-X. Deng and Y.-G. Man, *International Journal of Biological Sciences*, 2009, 5, 276-285.
16. P. R. Pandey, J. Saidou and K. Watabe, *Frontiers in bioscience : a journal and virtual library*, 2010, 15, 226-236.
17. M. J. Walsh, S. E. Holton, A. Kadjacsy-Balla and R. Bhargava, *Vibrational Spectroscopy*, 2012, 60, 23-28.
18. L. S. Leslie, A. Kadjacsy-Balla and R. Bhargava, *Medical Imaging : Digital Pathology*, 2015, 9420.
19. R. Bhargava, *Analytical and Bioanalytical Chemistry*, 2007, 389, 1155-1169.
20. D. C. Fernandez, R. Bhargava, S. M. Hewitt and I. W. Levin, *Nature Biotechnology*, 2005, 23, 469-474.
21. H. Brooke, B. V. Bronk, J. N. McCutcheon, S. L. Morgan and M. L. Myrick, *Applied Spectroscopy*, 2009, 63, 1293-1302.
22. J. Filik, M. D. Frogley, J. K. Pijanka, K. Wehbe and G. Cinque, *Analyst*, 2012, 137, 853-861.
23. P. Bassan, J. Lee, A. Sachdeva, J. Pissardini, K. M. Dorling, J. S. Fletcher, A. Henderson and P. Gardner, *Analyst*, 2013, 138, 144-157.
24. M. J. Pilling, P. Bassan and P. Gardner, *Analyst*, 2015, 140, 2383-2392.
25. P. Bassan, A. Sachdeva, J. H. Shanks, M. D. Brown, N. W. Clarke and P. Gardner, 2014, 9041, 90410D.
26. M. J. Baker, J. Trevisan, P. Bassan, R. Bhargava, H. J. Butler, K. M. Dorling, P. R. Fielden, S. W. Fogarty, N. J. Fullwood, K. A. Heys, C. Hughes, P. Lasch, P. L. Martin-Hirsch, B. Obinaju, G. D. Sockalingum, J. Sulé-Suso, R. J. Strong, M. J. Walsh, B. R. Wood, P. Gardner and F. L. Martin, *Nat. Protocols*, 2014, 9, 1771-1791.
27. P. Bassan, M. J. Weida, J. Rowlette and P. Gardner, *Analyst*, 2014, 139, 3856-3859.
28. Y. Yang, J. Sulé-Suso, G. D. Sockalingum, G. Kegelaer, M. Manfait and A. J. El Haj, *Biopolymers*, 2005, 78, 311-317.
29. E. Gazi, J. Dwyer, P. Gardner, A. Ghanbari-Siahkali, A. P. Wade, J. Miyan, N. P. Lockyer, J. C. Vickerman, N. W. Clarke, J. H. Shanks, L. J. Scott, C. A. Hart and M. Brown, *Journal of Pathology*, 2003, 201, 99-108.
30. L. Breiman, *Machine Learning*, 2001, 45, 5-32.
31. G. R. Lloyd and N. Stone, *Applied Spectroscopy*, 2015, 69, 1066-1073.
32. F. N. Pounder and R. Bhargava, 2009, vol. 7182, p. 718206.